206 related articles for article (PubMed ID: 23768250)
1. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study.
Morozova MA; Lepilkina TA; Rupchev GE; Beniashvily AG; Burminskiy DS; Potanin SS; Bondarenko EV; Kazey VI; Lavrovsky Y; Ivachtchenko AV
CNS Spectr; 2014 Aug; 19(4):316-23. PubMed ID: 23768250
[TBL] [Abstract][Full Text] [Related]
2. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
[TBL] [Abstract][Full Text] [Related]
3. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
Meltzer HY; Arvanitis L; Bauer D; Rein W;
Am J Psychiatry; 2004 Jun; 161(6):975-84. PubMed ID: 15169685
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
[TBL] [Abstract][Full Text] [Related]
5. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study.
Stryjer R; Strous R; Bar F; Shaked G; Shiloh R; Rozencwaig S; Grupper D; Buchman N; Kotler M; Rabey JM; Weizman A
Hum Psychopharmacol; 2004 Jul; 19(5):343-6. PubMed ID: 15252826
[TBL] [Abstract][Full Text] [Related]
6. Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study.
Mazeh D; Zemishlani H; Barak Y; Mirecki I; Paleacu D
Int Psychogeriatr; 2006 Sep; 18(3):429-36. PubMed ID: 16478570
[TBL] [Abstract][Full Text] [Related]
7. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
Rezaei F; Mohammad-Karimi M; Seddighi S; Modabbernia A; Ashrafi M; Salehi B; Hammidi S; Motasami H; Hajiaghaee R; Tabrizi M; Akhondzadeh S
J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
[TBL] [Abstract][Full Text] [Related]
8. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
[TBL] [Abstract][Full Text] [Related]
9. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.
Meskanen K; Ekelund H; Laitinen J; Neuvonen PJ; Haukka J; Panula P; Ekelund J
J Clin Psychopharmacol; 2013 Aug; 33(4):472-8. PubMed ID: 23764683
[TBL] [Abstract][Full Text] [Related]
10. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
11. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
[TBL] [Abstract][Full Text] [Related]
12. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
[TBL] [Abstract][Full Text] [Related]
14. AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation.
Ivachtchenko AV; Okun I; Aladinskiy V; Ivanenkov Y; Koryakova A; Karapetyan R; Mitkin O; Salimov R; Ivashchenko A
J Alzheimers Dis; 2017; 58(4):1043-1063. PubMed ID: 28550249
[TBL] [Abstract][Full Text] [Related]
15. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
Akhondzadeh S; Gerami M; Noroozian M; Karamghadiri N; Ghoreishi A; Abbasi SH; Rezazadeh SA
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1810-5. PubMed ID: 18727948
[TBL] [Abstract][Full Text] [Related]
16. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.
Lieberman JA; Papadakis K; Csernansky J; Litman R; Volavka J; Jia XD; Gage A;
Neuropsychopharmacology; 2009 Apr; 34(5):1322-9. PubMed ID: 19005465
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
19. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
Schoemaker JH; Jansen WT; Schipper J; Szegedi A
J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
[TBL] [Abstract][Full Text] [Related]
20. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
